COLLEGE STATION, Texas, May 5, 2025 /PRNewswire/ -- Matica Biotechnology, a specialized contract development and manufacturing organization (CDMO) for cell and gene therapies (CGT), has entered into a strategic partnership with the National Center for Therapeutics Manufacturing (NCTM), part of the Texas A&M Engineering Experiment Station. Together, the two organizations aim to provide a comprehensive, end-to-end service platform that supports CGT developers from early research through IND submission, clinical development, and commercialization.
By combining NCTM's early-stage research and development capabilities with Matica Bio's advanced manufacturing and regulatory expertise, the partnership offers a seamless solution for innovators in the CGT space—all within College Station, Texas.
Matica Biotechnology offers flexible CGT manufacturing services from its purpose-built facility, equipped with advanced technologies like the Ambr®250 system and single-use platforms. Its proprietary MatiMax™ cell line (HEK293/HEK293T-based) boosts productivity, helping biotech clients reach clinical milestones faster.
The National Center for Therapeutics Manufacturing (NCTM) supports early-stage development through its blend of academic, scientific, and industrial expertise. With bench-to-pilot scale bioprocessing and analytical capabilities, NCTM provides critical infrastructure for researchers, start-ups, and medical innovators.
"This partnership creates a unique synergy between academic innovation and industrial execution," said Paul Kim, Chief Executive Officer of Matica Biotechnology. "By combining NCTM's early discovery and development support with Matica Bio's clinical and commercial manufacturing capabilities, we're creating a powerful ecosystem that reduces costly barriers for CGT innovators."
"This collaboration exemplifies our mission to bridge academia and industry," said Dr. Baley Reeves, Director of the NCTM. "By aligning with Matica Biotechnology, we're expanding opportunities for translational research and accelerating the delivery of cutting-edge therapies to patients in need."
The integrated offering is expected to reduce development timelines, cost, enhance production efficiency, and streamline the path to market for next-generation therapies—empowering researchers and biotech companies to bring transformative treatments to patients faster.
About Matica Bio
Matica Biotechnology is a viral vector Contract Development and Manufacturing Organization (CDMO) that leverages advanced technologies at its purpose-built cGMP facility. With industry-leading expertise in process development, assay development, and cGMP manufacturing, Matica Bio serves as a trusted partner, seamlessly supporting its clients with streamlined operations throughout every stage of projects. Collaborating across five Matica sites worldwide, Matica Bio delivers excellence in the CDMO domain through innovations such as MatiMax™ proprietary cell lines, in-line process monitoring, and single-use technologies.
To learn more about Matica Bio, please visit www.maticabio.com.
About NCTM
The NCTM is an interdisciplinary workforce education and research center serving the global biopharmaceutical and vaccine manufacturing industries. NCTM provides enabling technologies to academic/medical researchers and start-ups through its blended infrastructure of academic, development, and industrial expertise and complete range of bench-to-pilot and Phase I scale bioprocess and analytical equipment. Our capabilities include early-stage process development, optimization, and scale-up for viral vectors, mRNA, and recombinant proteins.
To learn more about NCTM, please visit https://nctm.tamu.edu/
SOURCE Matica Biotechnology, Inc.
Share this article